| Literature DB >> 28799569 |
Tijana Skrepnik1, Silvija Gottesman2, Baldassarre Stea1.
Abstract
INTRODUCTION: Scleredema of Buschke is a rare connective tissue disorder presenting with woody thickening and induration of the nuchal and shoulder regions resulting in progressive decrease in the range of motion of the neck. Treatment options include several forms of systemic therapy with variable results. Local radiation therapy (RT) is often thought of as a secondary form of therapy. Few reports exist in the literature about the durability of its benefit, however. Here, we present a case report with the longest known follow-up after primary treatment with electron beam RT.Entities:
Year: 2015 PMID: 28799569 PMCID: PMC5506738 DOI: 10.1016/j.adro.2015.11.002
Source DB: PubMed Journal: Adv Radiat Oncol ISSN: 2452-1094
Radiation therapy use in the literature for scleredema of Buschke
| Author, y | No. of patients | Prior treatment | Energy | Dose | Outcome | Follow-up |
|---|---|---|---|---|---|---|
| Angeli-Besson et al., | 1 | Prednisolone, factor XIII, cyclofenil | 7-MeV electrons | 20 Gy/10 fx | Sustained PR | Not reported |
| Tamburin et al., | 1 | Topical, intralesional, systemic corticosteroids | Electrons | 20 Gy/10 fx | PR 6 wk | 2 y |
| Tobler et al., | 2 | Prednisolone | Mixed 12-MeV electrons and 6-MV photons | 20 Gy/10 fx | PR | 7 mo |
| Lee MW et al., | 3 | Not reported | Electrons | 24 Gy/12 fx | CR-PR | 7 mo |
| Bowen et al., | 3 | Unspecified systemic treatments | Photons 6 MV and | 20 Gy/10 fx | 3 initial PR, waning effects at 1-2 y | 2.5 years |
| Konemann et al., | 1 | Penicillin, psoralen ultraviolet A | 9-MeV electrons | 20 Gy/10 fx, reirradiation with | PR reirradiation required | 16 mo |
| Current paper, | 1 | None | 8-MeV electrons | 20 Gy/10 fx | PR in range of motion, CR in plaque induration | 6 y |
CR, complete response; fx, fraction; PR, partial response.
Figure 1(A, B) Treatment setup showing the top field covering the nuchal area and the lower field covering the shoulder regions. A gap was placed between the 2 fields to minimize dose overlap.
Figure 2No clinical evidence of residual plaque at 6 years’ follow-up.
Figure 3Improved range of motion 6 years after radiation therapy.